CBUS
Cibus, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
−2.22%Year over year
Reported trailing growth
- Revenue
- -10.3%
- EBITDA
- +78.1%
- EBIT
- +79.0%
- EPS
- +85.2%
- Free cash flow
- +13.8%
- Operating cash flow
- +13.0%
Forward estimates
Based on analyst estimates
- Revenue
- +171.1%
- EBITDA
- +7.4%
- EPS
- +44.0%
Three-year CAGR
- Revenue
- +185.1%
- EBITDA
- +62.4%
- EBIT
- +12.3%
- Net income
- +49.4%
- EPS
- +74.3%
- Free cash flow
- +13.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026